Search company, investor...
Search
Enlight Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

enlightbio.com

About Enlight Biosciences

Enlight is a Boston-based company established in partnership with major pharmaceutical companies to develop innovations that will fundamentally alter drug discovery and development. Enlight was founded by PureTech Ventures and a team of industry leaders and academic luminaries. Funded and guided by top pharmaceutical companies, Enlight proactively addresses critical unmet industry needs with innovations drawn from academic laboratories, startups, and ideas generated internally by the Enlight team.n

Enlight Biosciences Headquarters Location

222 Berkeley Street Suite 1040

Boston, Massachusetts, 02116,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Enlight Biosciences News

STAT Plus: Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?

Nov 27, 2019

Unlike most biotech startups, Enlight Biosciences was never expected to make any drugs. Instead, the company intended to develop a whole host of promising, biotech-adjacent ideas. One would help connect clinical researchers with interested companies. Another would figure out how to use ultrasounds to diagnose a common liver disease. Yet another would transform a class of injectable drugs into pills. Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

  • Where is Enlight Biosciences's headquarters?

    Enlight Biosciences's headquarters is located at 222 Berkeley Street, Boston.

  • Who are Enlight Biosciences's competitors?

    Competitors of Enlight Biosciences include CytoBioscience, Agilux Laboratories, Proteostasis Therapeutics, Celsis International, Genstruct and 12 more.

You May Also Like

A
Anthill Technologies

Anthill Technologies, Inc. is pioneering the development and commercialization of a unique proprietary applied chemistry operating system (ACOS�) and a novel high-speed chemical discovery engine based on this operating system to dramatically reduce the time, cost and risk factors associated with discovering and developing chemical compositions, pathways, processes and products for applications in both life science and non-life science markets.

A
AC PharmaChem

AC PharmaChem, Inc. is a fast growing company providing contract research and development services of medicinal chemistry, customer based organic synthesis of special chemical reagents, intermediates, reference compounds, and synthesis of focused libraries. The company's goal is to fully support the company's pharmaceutical and biotech partners to speed up and advance their drug discovery and innovation processes. At AC PharmaChem, the company have experienced medicinal and synthetic chemists utilizing synthetic techniques and instruments to provide cost efficient and on time delivery to meet the demands of the company's customers.

W
Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

F
Firebird Biomolecular Sciences

Firebird Biomolecular Sciences, Inc. supplies nucleic acid components, libraries, polymerases and software to support human diagnostics, synthetic biology and human therapy. A partner with the Foundation for Applied Molecular Evolution (FfAME), Firebird aims to provide a scientific, research-based environment to help create a more integrated science for the current century and to transfer technologies from basic research into products and processes to meet commercial and medical needs.

S
Sword Diagnostics

Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.

I
IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.